SGLT inhibitors

This article reviews expert perspectives on the efficacy and safety of SGLT inhibitors for cardiovascular and renal disease in type 1 diabetes, outlines translational insights from type 2 diabetes data, and proposes a roadmap for regulatory approval and clinical implementation focusing on surrogate endpoints and diabetic ketoacidosis risk mitigation.